News

News Archive

ESMO Annual Meeting 2019: Menarini Ricerche presents the preclinical characterization of MEN1611, a novel PI3K inhibitor in development for the treatm

ESMO Annual Meeting 2019: Menarini Ricerche presents the preclinical characterization of MEN1611, a novel PI3K inhibitor in development for the treatm

ESMO Annual Meeting 2019: Menarini Ricerche presents the preclinical characterization of MEN1611, a novel PI3K inhibitor in development for the treatment of breast cancer.

Promising results from the preclinical study conducted by Menarini Ricerche on MEN1611, a potent and selective orally available phosphatidylinositol 3-kinase (PI3K) inhibitor currently...

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Go to Follow our blog

Follow our blog

Discover our stories from all over the world

Read More